Riociguat
Overview
Riociguat is a soluble guanylate cyclase stimulator that works by increasing the sensitivity of soluble guanylate cyclase to endogenous nitric oxide. It is used in the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
API suppliers (5)
Suppliers of Riociguat evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 5 suppliers.
3 of 5 hold a GMP certificate on record in the EU or UK registers
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia2 active DMF GMP on record
- ZHEJIANG KINGLAND PHARMACEUTICAL CO LTD1 active DMF
- Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
- HONOUR LAB LTDIndia1 active DMF GMP on record
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (10 approved US products), the latest listed US patent on Riociguat expires 18 Feb 2034. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Riociguat? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.